about
Management of patients with biochemical recurrence after local therapy for prostate cancerAdverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complicationsSignificant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence.A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation OncologyA genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomyDisease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time.Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized studyEffectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-upSalvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy.Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy.Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
P2860
Q26849220-F7314E7F-642F-497D-B076-FE30797E63F8Q26852930-4E5CFE43-7ED9-45A1-99AD-6AC4003D29B2Q30489515-7BD1388F-8B4B-472C-B801-EB78A811E4D6Q34062324-F0BC7355-F9AE-4A95-8F7B-EA5B3C989D12Q34205971-7372473A-CDBF-4D6A-9DF3-F60425191B3BQ34505196-0CE27EED-AED3-4F3C-9D1E-56CCCD8C993DQ35096149-E5A2B705-F15B-436C-A1D1-53FF9B70CD60Q35188264-57519907-8013-441D-8C67-85AF70D08182Q36241230-01FE7C25-1EB6-4DEC-874C-260D22A6B02EQ37712068-8C099E5B-E9FC-4915-BD9F-248DBD942122Q38594174-04CBD9E2-6F50-43BC-8B5C-3D5EFD561588Q38869465-619F0232-C539-4337-BFE9-2E6DE14ACFEFQ41619535-3C6CD6D0-F188-4FCC-A35B-2D267C82689EQ43054848-8D538C1B-8A27-4D5C-9F45-BA89F6F6FC6AQ55192988-A424AD20-93DF-41F2-B645-F872BE2A5B9A
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Rising PSA in nonmetastatic prostate cancer.
@en
Rising PSA in nonmetastatic prostate cancer.
@nl
type
label
Rising PSA in nonmetastatic prostate cancer.
@en
Rising PSA in nonmetastatic prostate cancer.
@nl
prefLabel
Rising PSA in nonmetastatic prostate cancer.
@en
Rising PSA in nonmetastatic prostate cancer.
@nl
P2093
P1433
P1476
Rising PSA in nonmetastatic prostate cancer
@en
P2093
Judd W Moul
Lionel L Bañez
Stephen J Freedland
P304
1436-45; discussion 1449, 1452, 1454
P577
2007-11-01T00:00:00Z